神経内分泌癌:治療薬開発パイプライン動向(2014年下半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC5256IDB)
◆英語タイトル:Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5256IDB
◆発行日:2014年7月31日
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆ページ数:81
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[神経内分泌癌:治療薬開発パイプライン動向(2014年下半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2014’, provides an overview of the Neuro Endocrine (Carcinoid) Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Neuro Endocrine (Carcinoid) Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuro Endocrine (Carcinoid) Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuro Endocrine (Carcinoid) Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuro Endocrine (Carcinoid) Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neuro Endocrine (Carcinoid) Carcinoma Overview 7
Therapeutics Development 8
Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma – Overview 8
Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma – Comparative Analysis 9
Neuro Endocrine (Carcinoid) Carcinoma – Therapeutics under Development by Companies 10
Neuro Endocrine (Carcinoid) Carcinoma – Therapeutics under Investigation by Universities/Institutes 12
Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Neuro Endocrine (Carcinoid) Carcinoma – Products under Development by Companies 16
Neuro Endocrine (Carcinoid) Carcinoma – Products under Investigation by Universities/Institutes 17
Neuro Endocrine (Carcinoid) Carcinoma – Companies Involved in Therapeutics Development 18
F. Hoffmann-La Roche Ltd. 18
Amgen Inc. 19
Ipsen S.A. 20
Novartis AG 21
Lexicon Pharmaceuticals, Inc. 22
Jiangsu Hengrui Medicine Co., Ltd. 23
Camurus AB 24
Vascular Biogenics Ltd. 25
Advanced Accelerator Applications 26
Foresee Pharmaceuticals, LLC 27
Neuro Endocrine (Carcinoid) Carcinoma – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 32
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
telotristat etiprate – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
bevacizumab – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Lutathera – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pasireotide LAR – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ganitumab – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
octreotide acetate – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
SHR-1020 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VB-111 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
FP-002 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Peptides for Oncology – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BIM-23A758 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Neuro Endocrine (Carcinoid) Carcinoma – Recent Pipeline Updates 60
Neuro Endocrine (Carcinoid) Carcinoma – Dormant Projects 70
Neuro Endocrine (Carcinoid) Carcinoma – Discontinued Products 71
Neuro Endocrine (Carcinoid) Carcinoma – Product Development Milestones 72
Featured News & Press Releases 72
Oct 16, 2013: AAA reaches halfway recruitment milestone of cancer patients in Lutathera Pivotal Phase III trial 72
Sep 17, 2013: Ipsen announces positive top line results from phase III ELECT study of Somatuline in the control of symptoms in NET patients with a history of carcinoid syndrome 72
Jun 07, 2013: Cedars-Sinai Launches Phase III Clinical Trial Of Lutathera For Metastatic Carcinoid Cancer Patients 73
Oct 12, 2012: Lexicon Pharma Announces Positive Phase II Trial Results Of Telotristat Etiprate In Carcinoid Syndrome 74
Oct 12, 2012: Lexicon Pharma Initiates Phase III Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome 75
Mar 20, 2012: Lexicon’s Telotristat Etiprate Receives FDA Orphan Drug Designation For Carcinoid Syndrome Treatment 76
Oct 22, 2011: Lexicon To Present Data From Phase II Clinical Studies Of Telotristat Etiprate At NANETS In Minneapolis, US 77
Aug 09, 2011: Lexicon Announces Positive Results From Phase II Trial Of Telotristat Etiprate In Carcinoid Syndrome 77
Dec 16, 2010: Advanced Accelerator Applications Receives GMP Approval To Manufacture Lutate For Treatment Of Neuroendocrine Tumors 78
Dec 02, 2010: Pfizer Receives European Approval For SUTENT For New Indication In Progressive Pancreatic Neuroendocrine Tumors 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H2 2014 8
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 18
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Amgen Inc., H2 2014 19
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Ipsen S.A., H2 2014 20
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Novartis AG, H2 2014 21
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014 22
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 23
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Camurus AB, H2 2014 24
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Vascular Biogenics Ltd., H2 2014 25
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Advanced Accelerator Applications, H2 2014 26
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Foresee Pharmaceuticals, LLC, H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 60
Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects, H2 2014 70
Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products, H2 2014 71

List of Figures
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H2 2014 8
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Products, H2 2014 15
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Top 10 Target, H2 2014 29
Number of Products by Stage and Top 10 Target, H2 2014 30
Number of Products by Top 10 Mechanism of Action, H2 2014 32
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 33
Number of Products by Top 10 Route of Administration, H2 2014 35
Number of Products by Stage and Top 10 Route of Administration, H2 2014 36
Number of Products by Top 10 Molecule Type, H2 2014 37
Number of Products by Stage and Top 10 Molecule Type, H2 2014 38

*** 掲載企業 ***

F. Hoffmann-La Roche Ltd.
Amgen Inc.
Ipsen S.A.
Novartis AG
Lexicon Pharmaceuticals, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Camurus AB
Vascular Biogenics Ltd.
Advanced Accelerator Applications
Foresee Pharmaceuticals, LLC

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5256IDB )"神経内分泌癌:治療薬開発パイプライン動向(2014年下半期)" (英文:Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。